- Home
- NXL
as 03-25-2025 12:35pm EST
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 31.1M | IPO Year: | 2022 |
| Target Price: | $5.00 | AVG Volume (30 days): | 143.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $4.49 | Next Earning Date: | 03-14-2025 |
| Revenue: | $168,721 | Revenue Growth: | 52.35% |
| Revenue Growth (this year): | 175.37% | Revenue Growth (next year): | 334.78% |
Latest Nexalin Technology Inc. News
NXL Breaking Stock News: Dive into NXL Ticker-Specific Updates for Smart Investing
ACCESS Newswire
12 days ago
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
23 days ago
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Medical Device Network
23 days ago
UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD
GlobeNewswire
a month ago
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
GlobeNewswire
a month ago
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
MT Newswires
a month ago
Nexalin Technology Says Halo Clarity Headset Clinical Testing Gets UCSD Institutional Review Board Approval
GlobeNewswire
a month ago
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
GlobeNewswire
a month ago
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
Compare NXL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NXL Nexalin Technology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.